Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders

DUBLIN, January 29, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/6w8m93/biomarkers) has announced the addition of the "Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This report has a focus in biomarkers for neurodegenerative diseases and diagnostic applications in development. Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders. Although there are many techniques used to track neurodegenerative disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers.

In addition to covering background information, this report will highlight several technologies that have been developed for employing the use of biomarkers for neurodegenerative disease detection, analysis and therapeutic development. Including substantial background information, illustrated with graphics and figures, this report captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Three neurodegenerative disorders that are heavily focused on in this report include: Alzheimer's Disease/Mild Cognitive Impairment, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. Part II of the report will include all three of these disorders, highlighting specifics including background, history, and development of the disease. Deeper into the chapters, the report will unfold biomarkers under investigation, genetic targets, and an analysis of multiple studies investigating these elements.

Part III of the report makes a shift from neurobiomarkers to neurodiagnostics. This section highlights several diagnostics in play and in the making from a number of companies, identifying company strategies, research underway, hypotheses, and institution goals.

Further analysis appears in Part IV. This section includes a survey exclusively conducted for this report. With over 30 figures and graphics and an in depth analysis, this part features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications. Furthermore, the survey covers more than just the featured neurodegenerative disorders in this report, expanding to Multiple Sclerosis and Huntington's Disease.

Finally, this report concludes with clinical trial and pipeline data featuring targets and products from over 300 companies working in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis.

Key Topics Covered:

Executive Summary

Part I: Introduction And Background Information

Chapter 1: The Focus Of This Report
Chapter 2: Biomarkers And Their Clinical Utility
Chapter 3: Biomarkers In Neurodegenerative Disorders

Part II: Neurobiomarker Discovery And Development

Chapter 4: Mild Cognitive Impairment And Alzheimer'S Disease
Chapter 5: Parkinson'S Disease
Chapter 6: Amyotrophic Lateral Sclerosis

Part III: Neurodiagnostics And Biomarker Technologies
Chapter 7: Neurodiagnostics And Biomarker Technologies
Chapter 8: Penn State Hershey Medical Center
Chapter 9: Atlantic Biomarkers
Chapter 10: Quanterix
Chapter 11: Biostat Solutions, Inc. (Bssi)

Part IV: Survey Results
Chapter 12: Survey Results

Part V: Clinical Trials And Pipeline Information

For more information visit http://www.researchandmarkets.com/research/6w8m93/biomarkers

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net